| Year |
Title |
Altmetric |
| 2022
|
Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated with Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
Journal of Clinical Oncology.
40:3278-3288.
2022
|
|
| 2022
|
Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
Bone Marrow Transplantation.
57:1597-1599.
2022
|
|
| 2022
|
Combinatorial suicide gene strategies for the safety of cell therapies.
Frontiers in Immunology.
13.
2022
|
|
| 2022
|
Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.
Journal of Clinical Oncology.
40:1991-2003.
2022
|
|
| 2022
|
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Leukemia Research.
117.
2022
|
|
| 2022
|
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report.
Blood Advances.
6:2471-2479.
2022
|
|
| 2022
|
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
2022
|
|
| 2022
|
Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplantation.
2022
|
|
| 2021
|
Trends in Late Mortality and Life Expectancy after Allogeneic Blood or Marrow Transplantation over 4 Decades: A Blood or Marrow Transplant Survivor Study Report.
JAMA Oncology.
7:1626-1634.
2021
|
|
| 2021
|
Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.
American Journal of Hematology.
96:E396-E398.
2021
|
|
| 2021
|
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.
Bone Marrow Transplantation.
56:1364-1372.
2021
|
|
| 2020
|
Total body irradiation and risk of breast cancer after blood or marrow transplantation: A blood or marrow transplantation survivor study report.
Journal of Clinical Oncology.
38:2872-2882.
2020
|
|
| 2019
|
Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia.
Histopathology.
75:185-192.
2019
|
|
| 2019
|
Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.
Biology of Blood and Marrow Transplantation.
25:233-238.
2019
|
|
| 2018
|
Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
JAMA Oncology.
4.
2018
|
|
| 2018
|
Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
Leukemia.
32:2706-2709.
2018
|
|
| 2018
|
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.
Bone Marrow Transplantation.
53:1345-1348.
2018
|
|
| 2018
|
Two cases and a review of graft-versus-host disease and the role of hepatitis C treatment in liver transplant patients
2018
|
|
| 2018
|
Late mortality after autologous blood or marrow transplantation in childhood: A Blood or Marrow Transplant Survivor Study-2 report.
Blood.
131:2720-2729.
2018
|
|
| 2017
|
Agranulocytosis - Sequelae of Chronic Cocaine Use: Case Series and Literature Review..
Cureus.
9:e1221.
2017
|
|
| 2017
|
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia..
PLoS One.
12:e0172640.
2017
|
|
| 2017
|
Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure.
Bone Marrow Transplantation.
52:157-158.
2017
|
|
| 2016
|
In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia.
PLoS One.
11.
2016
|
|
| 2016
|
Acute myofascitis as a manifestation of chronic graft-versus-host disease.
Muscle and Nerve.
53:327-329.
2016
|
|
| 2016
|
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.
Cancer Causes and Control.
27:81-91.
2016
|
|
| 2012
|
How we closed the gap between red blood cell utilization and whole blood collections in our institution.
Transfusion.
52:1857-1867.
2012
|
|
| 2012
|
Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients.
Supportive Care in Cancer.
20:1405-1415.
2012
|
|
| 2007
|
Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation.
Clinical advances in hematology & oncology : H&O.
5:882-884.
2007
|
|
| 2006
|
Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: Determination of the best diagnostic approach.
Bone Marrow Transplantation.
38:371-376.
2006
|
|
| 2006
|
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen.
Biology of Blood and Marrow Transplantation.
12:770-777.
2006
|
|
| 2006
|
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up.
Neuro-Oncology.
8:183-188.
2006
|
|
| 2004
|
Adoptive Immunotherapy with Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes for Recurrent, EBV-Positive Hodgkin Disease.
Cancer.
100:1892-1901.
2004
|
|
| 2003
|
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
Journal of Neuro-Oncology.
65:127-134.
2003
|
|
| 2002
|
Fungal brain abscess in transplant recipients: Epidemiologic, microbiologic, and clinical features.
Clinical Transplantation.
16:419-424.
2002
|
|
| 2002
|
A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
Biology of Blood and Marrow Transplantation.
8:619-624.
2002
|
|
| 2001
|
Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1].
Blood.
97:3313-3314.
2001
|
|
| 2001
|
Invasive mold infections in allogeneic bone marrow transplant recipients.
Clinical Infectious Diseases.
32:1319-1324.
2001
|
|
| 2000
|
Adoptive immunotherapy with allogeneic EBV CTL for organ transplant patients with ebv induced lymphoproliferative disease.
Blood.
96.
2000
|
|
| 2000
|
Diagnosis of gastrointestinal graft-versus-host disease.
American Journal of Gastroenterology.
95:3034-3038.
2000
|
|
| 2000
|
Diagnosis of gastrointestinal graft-versus-host disease..
American Journal of Gastroenterology.
95:3034-3038.
2000
|
|
| 2000
|
A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Human gene therapy. Clinical development.
11:1453-1463.
2000
|
|
| 2000
|
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Neuro-Oncology.
2:114-119.
2000
|
|
| 1997
|
Bone marrow transplantation for non-Hodgkin's lymphoma: A review.
American Journal of the Medical Sciences.
313:228-235.
1997
|
|
| 1996
|
Malignancy-associated pulmonary veno-occlusive disease: Report of a case following autologous bone marrow transplantation and review.
Bone Marrow Transplantation.
18:755-760.
1996
|
|
| 1995
|
Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
Bone Marrow Transplantation.
16:353-358.
1995
|
|
| 1994
|
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Journal of Clinical Oncology.
12:1890-1901.
1994
|
|
| 1993
|
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
Investigational New Drugs.
11:169-179.
1993
|
|
| 1993
|
Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation.
Bone Marrow Transplantation.
12:541-546.
1993
|
|
| 1993
|
Immunotoxins for the therapy of graft versus host disease..
Cancer Treatment and Research.
68:133-144.
1993
|
|
